Display options
Share it on

Front Pharmacol. 2021 May 18;12:667572. doi: 10.3389/fphar.2021.667572. eCollection 2021.

Protective Role of .

Frontiers in pharmacology

Eleonora Starikova, Jennet Mammedova, Arina Ozhiganova, Aleksandra Lebedeva, Anna Malashicheva, Daria Semenova, Evgeniia Khokhlova, Eleonora Mameli, Andrea Caporali, Jimi Wills, Alexey Sokolov

Affiliations

  1. Laboratory of Immunoregulation, Department of Immunology, Institute of Experimental Medicine, St. Petersburg, Russian Federation.
  2. Laboratory of General Immunology, Department of Immunology, Institute of Experimental Medicine, St. Petersburg, Russian Federation.
  3. Laboratory of Molecular Cardiology, Almazov National Medical Research Centre, St. Petersburg, Russian Federation.
  4. Laboratory of Regenerative Biomedicine, Institute of Cytology RAS, St. Petersburg, Russian Federation.
  5. Laboratory of Vascular Biology, University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
  6. Cancer Research United Kingdom Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
  7. Laboratory of Biochemical Genetics, Department of Molecular Genetics, Institute of Experimental Medicine, St. Petersburg, Russian Federation.

PMID: 34084140 PMCID: PMC8167060 DOI: 10.3389/fphar.2021.667572

Abstract

Acute liver injury in its terminal phase trigger systemic inflammatory response syndrome with multiple organ failure. An uncontrolled inflammatory reaction is difficult to treat and contributes to high mortality. Therefore, to solve this problem a search for new therapeutic approaches remains urgent. This study aimed to explore the protective effects of

Copyright © 2021 Starikova, Mammedova, Ozhiganova, Lebedeva, Malashicheva, Semenova, Khokhlova, Mameli, Caporali, Wills and Sokolov.

Keywords: IL-6; M. edulis hydrolysate; VCAM-1; acute liver injury; nitric oxide; vascular permeability

Conflict of interest statement

The authors declare that this study received funding from N2 Pharmaceuticals Ltd. (United Kingdom).

References

  1. Hepatology. 1995 Nov;22(5):1538-46 - PubMed
  2. Food Chem. 2014 Jan 1;142:48-60 - PubMed
  3. Bioresour Technol. 2005 Sep;96(14):1624-9 - PubMed
  4. J Immunol Methods. 1991 May 17;139(1):107-14 - PubMed
  5. J Emerg Trauma Shock. 2010 Jan;3(1):26-35 - PubMed
  6. N Engl J Med. 2010 Aug 12;363(7):689-91 - PubMed
  7. Methods Mol Biol. 2016;1396:109-114 - PubMed
  8. F1000Res. 2018 Sep 28;7: - PubMed
  9. Nat Protoc. 2007;2(3):481-5 - PubMed
  10. Med Res Rev. 2020 Jan;40(1):158-189 - PubMed
  11. Crit Care. 2019 May 31;23(1):196 - PubMed
  12. Int J Mol Sci. 2018 Jan 04;19(1): - PubMed
  13. Biomed Pharmacother. 2019 Mar;111:527-536 - PubMed
  14. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7919-23 - PubMed
  15. Free Radic Biol Med. 1998 Sep;25(4-5):434-56 - PubMed
  16. PLoS One. 2015 Jul 09;10(7):e0132367 - PubMed
  17. Int J Clin Exp Pathol. 2014 Sep 15;7(10):6626-34 - PubMed
  18. Nutrients. 2018 Apr 13;10(4): - PubMed
  19. J Clin Invest. 2001 Feb;107(4):439-47 - PubMed
  20. J Cereb Blood Flow Metab. 2016 May;36(5):862-90 - PubMed
  21. Braz J Infect Dis. 2011 Jul-Aug;15(4):332-8 - PubMed
  22. J Vis Exp. 2018 Jun 19;(136): - PubMed
  23. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5939-43 - PubMed
  24. J Cell Mol Med. 2018 Nov;22(11):5573-5582 - PubMed
  25. Food Chem. 2016 Jul 1;202:9-14 - PubMed
  26. Ann Emerg Med. 2006 Nov;48(5):583-90, 590.e1 - PubMed
  27. J Hepatol. 2004 Nov;41(5):773-81 - PubMed
  28. Mar Drugs. 2019 May 10;17(5): - PubMed
  29. Int J Mol Sci. 2018 Jul 19;19(7): - PubMed
  30. Lab Invest. 1999 Oct;79(10):1181-99 - PubMed
  31. Int J Mol Med. 2018 Sep;42(3):1756-1764 - PubMed
  32. J Cell Physiol. 2019 Mar;234(3):2277-2295 - PubMed
  33. Food Chem. 2013 Jun 1;138(2-3):1713-9 - PubMed
  34. Adv Exp Med Biol. 2017;975 Pt 2:931-942 - PubMed

Publication Types